On this episode we welcome Dr. Staci Gruber, Director of the Cognitive and Clinical Neuroimaging Core at McLean Hospital’s Brain Imaging Center and an Associate Professor of Psychiatry at Harvard Medical School. Dr. Gruber has spent decades investigating how both recreational and medical cannabis use affects the brain. In 2014, Dr. Gruber launched Marijuana Investigations for Neuroscientific Discovery (MIND), the first-ever program of its kind designed to clarify the specific effects of medical cannabis use.
What she and her team have found is that not only do medical cannabis patients tend to perform better on cognitive tests when compared to recreational users, but medical cannabis patients tend to outperform themselves when compared to tests administered before they started treatment.
Staci explores why this is the case in the podcast, as well as results from MIND’s double-blind, placebo-controlled CBD clinical trial for anxiety, which used a high-CBD whole-plant extract. Interesting observations from the study include:
Medicinal Genomics invites you to listen as we talk with cannabis industry experts, discussing topics from bench to bedside as part of our NEW CannMed Coffee Talk Podcast Series. Get a sneak peak into the 4 FOCUS AREAS that will be covered in separate speaker tracks at CannMed 2021 in Pasadena, CA on April 12-14, 2021.